Peter Buzy

Pete Buzy is an industry veteran, who led one of the fastest expanding Mid- Atlantic Biotech companies. Having joined Paragon Bioservices in 2014 as an investor and Chief Operating Officer, he later moved into the role of President & Chief Executive Officer and Board member. His expertise in building strong and focused leadership teams and growing emerging technology companies was instrumental in the value creation of Paragon, which resulted in its purchase by Catalent (NYSE: CTLT) in 2019 for $1.2B one of the largest PE backed transactions in the region over the past decade.

Prior to joining Paragon, Pete spent more than 13 years as a senior executive at Martek Biosciences Corporation (NASDAQ: MATK), a leader in the innovation, development, production, and sale of high-value products from microbial sources. He played a key role in transforming Martek’s business from an R&D company to a fully integrated and profitable commercial organization, setting the stage for Martek’s sale to Royal DSM NV in 2011 for $1.1B.

Pete is currently an Advisory Partner with NewSpring Capital and is also on the board of several healthcare companies.